Recruiting
Neoplasm
RecruitingStudy of ALE.
InvestigationalNo placebo
Study of ALE.
InvestigationalNo placebo
Countries:
Spain
Spain- Participants:18–64 years · 65+ years
- Substances:ALE.P03
- Sponsor:Alentis Therapeutics AG
Back to SpainClinical trials in Murcia – page 6
444 clinical trials in Murcia, Spain across 3 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.
Our site in SpainEnsayosClinicos.es(opens in a new tab)Murcia at a glance
444
clinical trials
- Research sites3
Recruiting
Study of ribociclib with or without chemotherapy for patients with hormone receptor positive, HER2 negative early breast cancer at intermediate risk
Registered drugNo placebo
Study of ribociclib with or without chemotherapy for patients with hormone receptor positive, HER2 negative early breast cancer at intermediate risk
Registered drugNo placebo
- Disease:Hormone receptor positive HER2 negative breast cancer
- Substances:AnastrozoleCyclophosphamide+12
Countries:Spain
Spain- Participants:18–64 years · 65+ years
- Substances:Anastrozole
- Sponsor:Unicancer
Recruiting
Endometrial cancer metastatic
RecruitingA Study of Puxitatug Samrotecan Compared to Chemotherapy for Patients with Advanced Endometrial Cancer After Previous Platinum and Immunotherapy Treatment
Registered drugNo placebo
A Study of Puxitatug Samrotecan Compared to Chemotherapy for Patients with Advanced Endometrial Cancer After Previous Platinum and Immunotherapy Treatment
Registered drugNo placebo
- Disease:Endometrial cancer metastatic
- Substances:AZD8205Doxorubicin+1
Countries:Spain
Spain- Participants:18–64 years · 65+ years
- Substances:AZD8205
- Sponsor:AstraZeneca AB
Recruiting
Hypertrophic cardiomyopathy+1
RecruitingA study testing ninerafaxstat compared to placebo in patients with symptomatic non-obstructive hypertrophic cardiomyopathy
Investigational
A study testing ninerafaxstat compared to placebo in patients with symptomatic non-obstructive hypertrophic cardiomyopathy
Investigational
- Disease:Hypertrophic cardiomyopathyCardiomyopathy
- Substances:–
Countries:Spain
Spain- Participants:18–64 years · 65+ years
- Sponsor:Imbria Pharmaceuticals Inc.
Recruiting
Breast cancer+2
RecruitingA Study Comparing RLY-2608 and Fulvestrant with Capivasertib and Fulvestrant for Patients with PIK3CA-Mutant Hormone Receptor Positive, HER2-Negative Advanced Breast Cancer
Registered drugNo placebo
A Study Comparing RLY-2608 and Fulvestrant with Capivasertib and Fulvestrant for Patients with PIK3CA-Mutant Hormone Receptor Positive, HER2-Negative Advanced Breast Cancer
Registered drugNo placebo
- Disease:Breast cancerBreast cancer metastatic+1
- Substances:CapivasertibFulvestrant+1
Countries:Spain
Spain- Participants:18–64 years · 65+ years
- Substances:Capivasertib
- Sponsor:Relay Therapeutics Inc.
Recruiting
Ischaemic stroke
RecruitingA Study of TGD001 in Patients with Acute Ischemic Stroke to Test Safety and Effectiveness
Registered drug
A Study of TGD001 in Patients with Acute Ischemic Stroke to Test Safety and Effectiveness
Registered drug
- Disease:Ischaemic stroke
- Substances:Sodium chloride solution 0.9%Urokinase, catalytic domain, fused with a single-chain antibody against VON willebrand factor
Countries:Spain
Spain- Participants:18–64 years · 65+ years
- Substances:Sodium chloride solution 0.9%
- Sponsor:TargED Biopharmaceuticals B.V.
Recruiting
Colorectal adenocarcinoma+2
RecruitingStudy of chemotherapy drug combination with or without heated chemotherapy in the abdomen for patients with advanced colon cancer
Registered drugNo placebo
Study of chemotherapy drug combination with or without heated chemotherapy in the abdomen for patients with advanced colon cancer
Registered drugNo placebo
- Disease:Colorectal adenocarcinomaColorectal cancer stage II+1
- Substances:CapecitabineFluorouracil+3
Countries:Spain
Spain- Participants:18–64 years · 65+ years
- Substances:Capecitabine
- Sponsor:Fundacion Para La Investigacion Biomedica De Cordoba
Recruiting
Triple negative breast cancer
RecruitingA study comparing datopotamab deruxtecan with durvalumab versus datopotamab deruxtecan alone for patients with PDL1-negative metastatic triple-negative breast cancer
Registered drugNo placebo
A study comparing datopotamab deruxtecan with durvalumab versus datopotamab deruxtecan alone for patients with PDL1-negative metastatic triple-negative breast cancer
Registered drugNo placebo
- Disease:Triple negative breast cancer
- Substances:DurvalumabDatopotamab Deruxtecan
Countries:Spain
Spain- Participants:18–64 years
- Substances:Durvalumab
- Sponsor:Queen Mary University Of London
Recruiting
Chronic graft versus host disease
RecruitingStudy of axatilimab compared to standard therapy in children with chronic graft-versus-host disease who have previously received at least 2 treatments
InvestigationalNo placebo
Study of axatilimab compared to standard therapy in children with chronic graft-versus-host disease who have previously received at least 2 treatments
InvestigationalNo placebo
- Disease:Chronic graft versus host disease
- Substances:Axatilimab
Countries:Spain
Spain- Participants:0–17 years
- Substances:Axatilimab
- Sponsor:Incyte Corp.
Recruiting
Plasma cell myeloma
RecruitingStudy of daratumumab, teclistamab and talquetamab combination treatment for frail patients with newly diagnosed multiple myeloma
Registered drugNo placebo
Study of daratumumab, teclistamab and talquetamab combination treatment for frail patients with newly diagnosed multiple myeloma
Registered drugNo placebo
- Disease:Plasma cell myeloma
- Substances:DaratumumabTalquetamab+1
Countries:Spain
Spain- Participants:18–64 years · 65+ years
- Substances:Daratumumab
- Sponsor:Emn Trial Office S.r.l. Impresa Sociale
Recruiting
Immune thrombocytopenia
RecruitingStudy of oral rilzabrutinib for adults with immune thrombocytopenia who did not respond to first-line treatment
InvestigationalNo placebo
Study of oral rilzabrutinib for adults with immune thrombocytopenia who did not respond to first-line treatment
InvestigationalNo placebo
- Disease:Immune thrombocytopenia
- Substances:Rilzabrutinib
Countries:Spain
Spain- Participants:18–64 years · 65+ years
- Substances:Rilzabrutinib
- Sponsor:Sanofi-Aventis Recherche & Developpement
Recruiting
Spinal fusion surgery
RecruitingComparing Ropivacaine with Epinephrine Injection Methods for Pain and Bleeding Control in Patients Undergoing Lumbar Fusion Surgery
Registered drugNo placebo
Comparing Ropivacaine with Epinephrine Injection Methods for Pain and Bleeding Control in Patients Undergoing Lumbar Fusion Surgery
Registered drugNo placebo
- Disease:Spinal fusion surgery
- Substances:EpinephrineRopivacaine Hydrochloride
Countries:Spain
Spain- Participants:18–64 years · 65+ years
- Substances:Epinephrine
- Sponsor:Fundacio Institut De Recerca De L Hospital De La Santa Creu I Sant Pau
Other cities in Spain
The busiest research cities in the country
- Madrid3 330 trials · 24 research sites
- Barcelona3 182 trials · 23 research sites
- Valencia1 800 trials · 8 research sites
- Sevilla1 657 trials · 4 research sites
- Malaga1 063 trials · 4 research sites
- L'hospitalet De Llobregat988 trials · 4 research sites
- Badalona775 trials · 3 research sites
- Pamplona761 trials · 1 research site
Clinical research in Murcia
What the registry says about research in the country
01 Oncology - Blood Cancers
Innovative clinical trials focusing on hematologic malignancies, including studies of new therapeutic combinations for chronic lymphocytic leukemia, multiple myeloma, and acute myeloid leukemia. Research aims to evaluate novel treatment approaches and improve patient outcomes.
- Chronic Myeloid Leukemia treatment optimization
- Multiple Myeloma therapy combinations
- Lymphoma management strategies
02 Solid Tumors
Comprehensive studies evaluating treatments for various solid tumors, including innovative approaches for breast cancer, melanoma, and gastric cancer. Research focuses on targeted therapies and immunotherapy combinations.
- Advanced breast cancer treatments
- Melanoma brain metastases therapy
- Gastrointestinal cancer interventions
03 Neurological Conditions
Groundbreaking research in neurological disorders, particularly focusing on multiple sclerosis and acute cerebral ischemic stroke. Studies aim to evaluate new therapeutic agents and improve patient outcomes.
- Stroke treatment innovations
- Multiple sclerosis management
- Neurological therapeutic advances